Skip to main content


3T Biosciences Debuts with $40 Million Series A Financing

By News

Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations Company secured exclusive license with Stanford University for novel TCR-mimetic discovery platform and development stage MAGE-A3 TCRs Stefan Scherer, M.D., Ph.D., named president and CEO, and Christopher DeRespino, MBA, appointed…

Read More